產(chǎn)品名稱(chēng) | 自噬相關(guān)蛋白4A抗體 |
英文名稱(chēng) | Anti-ATG4A |
規(guī)格 | 0.2ml/200μg |
濃度 | 1mg/1ml |
價(jià)格 | 來(lái)電可享受優(yōu)惠 |
英文名稱(chēng) Anti-ATG4A
中文名稱(chēng) 自噬相關(guān)蛋白4A抗體
濃 度 1mg/1ml
規(guī)格 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類(lèi)型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Cow, Rabbit
產(chǎn)品類(lèi)型 一抗
研究領(lǐng)域 腫瘤免疫學(xué)細(xì)胞凋亡轉(zhuǎn)錄調(diào)節(jié)因子
蛋白分子量 predicted molecular weight: 45kDa
性 狀 Lyophilized or Liquid
免疫原 KLH conjugated synthetic peptide derived from human ATG4A
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ)存液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year.
別 名 ATG4A is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes.
